 |
|
|
| |
Weight change over 48 weeks after the transition to
dolutegravir-based therapy- a prospective study in Uganda
|
| |
| |
CROI 2023 Feb 20-23
Jen Manne-Goehler1,2,4, Richard Migisha5, Winnie Muyindike5, Geoffrey Chen2, Taing Nandi Aung2, Victoria Nanfuka5, Nimusiima Komukama5, Mahomed-Yunus S. Moosa8, Ravindra K. Gupta10,11, Deenan Pillay9,
Vincent C. Marconi7, Bethany Hedt-Gauthier3,7, Mark J. Siedner2,3,4,11, Suzanne M. McCluskey2,3,4
1 Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA, 2 Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA, 3 Harvard Medical School, Boston, MA, USA 4 Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA, 5 Mbarara University of Science and Technology, Mbarara, Uganda, 6 Harvard T. H. Chan School of Public Health, Boston, MA, USA, 7 Emory University School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA, 8 Department of Infectious Diseases, University of KwaZulu-Natal, Durban, South Africa, 9 University College London, London, United Kingdom, 10 University of Cambridge, Cambridge, United Kingdom, 11 Africa Health Research Institute, Durban, South Africa
|
| |
|
|
|
|
|
